Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
BioDrugs
Erschienen in: BioDrugs 3/2008

01.05.2008 | Novel Therapeutic Strategies

Peptide Inhibition of HIV-1

Current Status and Future Potential

verfasst von: Dr Neerja Kaushik-Basu, Amartya Basu, Dylan Harris

Erschienen in: BioDrugs | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

More than 2 decades of intensive research has focused on defining replication mechanisms of HIV type 1 (HIV-1), the etiologic agent of AIDS. The delineation of strategies for combating this viral infection has yielded many innovative approaches toward this end. HIV-1 is a lentivirus in the family retroviridae that is relatively small with regard to both structure and genome size, having a diploid RNA genome of approximately 9 kb, with only three major genes and several gene products resulting from alternate splicing and translational frameshifting. Most marketed drugs for treating AIDS are inhibitors of HIV-1 reverse transcriptase or protease enzymes, but new targets include the integrase enzyme, cell surface interactions that facilitate viral entry, and also virus particle maturation and assembly. The emergence of drug-resistant variants of HIV-1 has been the main impediment to successful treatment of AIDS. Thus, there is a pressing need to develop novel treatment strategies targeting multiple stages of the virus life-cycle. Research efforts aimed at developing successful means for combating HIV-1 infection have included development of peptide inhibitors of HIV-1. This article summarizes past and current endeavors in the development of peptides that inhibit replication of HIV-1 and the role of peptide inhibitors in the search for new anti-HIV drugs.
Literatur
1.
2.
3.
Advancing HIV prevention: new strategies for a changing epidemic. Morb Mortal Wkly Rep 2003; 52: 329-32
4.
Golden MR, Brewer DD, Kurth A, et al. Importance of sex partner HIV status in HIV risk assessment among men who have sex with men. J Acquir Immune Defic Syndr 2004; 36(2): 734–42PubMedCrossRef
5.
Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242(4882): 1168–71PubMedCrossRef
6.
Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242(4882): 1171–3PubMedCrossRef
7.
Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society — USA panel. Top HIV Med 2006; 14(3): 827–43PubMed
8.
Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006; 57(4): 619–27PubMedCrossRef
9.
Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gpl20 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393(6686): 648–59PubMedCrossRef
10.
Zhou T, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gpl20. Nature 2007; 445(7129): 732–7PubMedCrossRef
11.
Galanakis PA, Spyroulias GA, Rizos A, et al. Conformational properties of HIV-1 gp120/V3 immunogenic domains. Curr Med Chem 2005; 12(13): 1551–68PubMedCrossRef
12.
Moore JP, Cao Y, Conley AJ, et al. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. J Acquir Immune Defic Syndr 1994; 7(4): 332–9PubMed
13.
Moore JP, Cao Y, Ho DD, et al. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68(8): 5142–55PubMed
14.
Moore JP, Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996; 70(3): 1863–72PubMed
15.
Sodroski J, Wyatt R, Olshevsky U, et al. Conformation of the HIV-1 gp120 envelope glycoprotein. Antibiotics Chemother 1996; 48: 184–7
16.
Ferrer M, Harrison SC. Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J Virol 1999; 73(7): 5795–802PubMed
17.
Biorn AC, Cocklin S, Madani N, et al. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry 2004; 43(7): 1928–38PubMedCrossRef
18.
Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41(7): 1521–30PubMed
19.
McFadden K, Cocklin S, Gopi H, et al. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins 2007; 67(3): 617–29PubMedCrossRef
20.
Cocklin S, Gopi H, Querido B, et al. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor. J Virol 2007; 81(7): 3645–8PubMedCrossRef
21.
Boggiano C, Jiang S, Lu H, et al. Identification of a D-amino acid decapeptide HIV-1 entry inhibitor. Biochem Biophys Res Commun 2006; 347(4): 909–15PubMedCrossRef
22.
Zhou Y, Kurihara T, Ryseck RP, et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998; 160: 4018–25PubMed
23.
Thapa M, Kuziel WA, Carr DJ. Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization. J Virol 2007; 81: 3704–13PubMedCrossRef
24.
Ajuebor MN, Wondimu Z, Hogaboam CM, et al. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am J Pathol 2007; 170: 1975–88PubMedCrossRef
25.
Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667–73PubMedCrossRef
26.
Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367–77PubMedCrossRef
27.
Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722–5PubMedCrossRef
28.
Pasi KJ, Sabin CA, Jenkins PV, et al. The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. Br J Haematol 2000; 111: 136–42PubMedCrossRef
29.
Taylor JM, Wang Y, Ahdieh L, et al. Causal pathways for CCR5 genotype and HIV progression. J Acquir Immune Defic Syndr 2000; 23: 160–71PubMed
30.
Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194(7): 926–30PubMedCrossRef
31.
Marozsan AJ, Kuhmann SE, Morgan T, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005; 338(1): 182–99PubMedCrossRef
32.
Kuhmann SE, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78(6): 2790–807PubMedCrossRef
33.
Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005; 16(6): 339–54PubMed
34.
Pastore C, Ramos A, Mosier DE. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 2004; 78(14): 7565–74PubMedCrossRef
35.
Agrawal L, VanHorn-Ali Z, Berger EA, et al. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 2004; 103(4): 1211–7PubMedCrossRef
36.
Imai M, Baranyi L, Okada N, et al. Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments. Biochem Biophys Res Commun 2007; 353(4): 851–6PubMedCrossRef
37.
Zhou N, Luo Z, Luo J, et al. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. Biochemistry 2000; 39(13): 3782–7PubMedCrossRef
38.
Luo Z, Fan X, Zhou N, et al. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II. Biochemistry 2000; 39(44): 13545–50PubMedCrossRef
39.
Tamamura H, Araki T, Ueda S, et al. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem 2005; 48(9): 3280–9PubMedCrossRef
40.
Tamamura H, Mizumoto M, Hiramatsu K, et al. Topochemical exploration of potent compounds using retro-enantiomer libraries of cyclic pentapeptides. Org Biomol Chem 2004; 2(8): 1255–7PubMedCrossRef
41.
Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89(2): 263–73PubMedCrossRef
42.
Kliger Y, Gallo SA, Peisajovich SG, et al. Mode of action of an antiviral peptide from HIV-1: inhibition at a post-lipid mixing stage. J Biol Chem 2001; 276(2): 1391–7PubMedCrossRef
43.
Murakami T, Zhang TY, Koyanagi Y, et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 1999; 73(9): 7489–96PubMed
44.
Arakaki R, Tamamura H, Premanathan M, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999; 73(2): 1719–23PubMed
45.
Murakami T, Nakajima T, Koyanagi Y, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997; 186(8): 1389–93PubMedCrossRef
46.
Nakashima H, Masuda M, Murakami T, et al. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob Agents Chemother 1992; 36(6): 1249–55PubMedCrossRef
47.
Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994; 91(21): 9770–4PubMedCrossRef
48.
Shu W, Liu J, Ji H, et al. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 2000; 39(7): 1634–42PubMedCrossRef
49.
50.
Maggi P, Ladisa N, Cinori E, et al. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 2004; 53(4): 678–81PubMedCrossRef
51.
Lalezari JP, DeJesus E, Northfelt DW, et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003; 8(4): 279–87PubMed
52.
Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17(5): 691–8PubMedCrossRef
53.
Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18(10): 685–93PubMedCrossRef
54.
Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46(6): 1896–905PubMedCrossRef
55.
Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005; 7(3): 139–47PubMed
56.
Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004; 18(8): 1137–46PubMedCrossRef
57.
Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society — USA Panel. JAMA 2004; 292(2): 251–65PubMedCrossRef
58.
Lu J, Sista P, Giguel F, et al. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004; 78: 4628–37PubMedCrossRef
59.
Reeves JD, Lee FH, Miamidian JL, et al. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005; 79: 4991–9PubMedCrossRef
60.
Lalezari JP, Beilos NC, Sathasivam K, et al. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvir-tide-containing treatment regimen. J Infect Dis 2005; 191(7): 1155–63PubMedCrossRef
61.
62.
Ray N, Harrison JE, Blackburn LA, et al. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol 2007; 81(7): 3240–50PubMedCrossRef
63.
Eron JJ, Gulick RM, Bartlett JA, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis 2004; 189(6): 1075–83PubMedCrossRef
64.
Martin-Carbonero L. Discontinuation of the clinical development of fusion inhibitor T-1249. AIDS Rev 2004; 6(1): 61PubMed
65.
Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75(18): 8605–14PubMedCrossRef
66.
Heil ML, Decker JM, Sfakianos JN, et al. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004; 78(14): 7582–9PubMedCrossRef
67.
Egelhofer M, Brandenburg G, Martinius H, et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004; 78: 568–75PubMedCrossRef
68.
Dervillez X, Huther A, Schuhmacher J, et al. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. Chem Med Chem 2006; 1: 330–9PubMed
69.
Munch J, Standker L, Adermann K, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007; 129(2): 263–75PubMedCrossRef
70.
Wang J, Smerdon SJ, Jager J, et al. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci U S A 1994; 91(15): 7242–6PubMedCrossRef
71.
Le Grice SF, Naas T, Wohlgensinger B, et al. Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J 1991; 10(12): 3905–11PubMed
72.
Muller B, Restle T, Weiss S, et al. Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli. J Biol Chem 1989; 264(24): 13975–8PubMed
73.
Baillon JG, Nashed NT, Kumar A, et al. A leucine zipper-like motif may mediate HIV reverse transcriptase subunit binding. New Biol 1991; 3(10): 1015–9PubMed
74.
Harris D, Lee R, Misra HS, et al. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 1998; 37(17): 5903–8PubMedCrossRef
75.
Divita G, Restle T, Goody RS, et al. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J Biol Chem 1994; 269(18): 13080–3PubMed
76.
Divita G, Rittinger K, Geourjon C, et al. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. J Mol Biol 1995; 245(5): 508–21PubMedCrossRef
77.
Morris MC, Robert-Hebmann V, Chaloin L, et al. A new potent HIV-1 reverse transcriptase inhibitor: a synthetic peptide derived from the interface subunit domains. J Biol Chem 1999; 274(35): 24941–6PubMedCrossRef
78.
Depollier J, Hourdou ML, Aldrian-Herrada G, et al. Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization. Biochemistry 2005; 44(6): 1909–18PubMedCrossRef
79.
Oz Gleenberg I, Herschhorn A, Goldgur Y, et al. Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase. Arch Biochem Biophys 2007; 458(2): 202–12CrossRef
80.
Gleenberg IO, Herschhorn A, Hizi A. Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). J Mol Biol 2007; 369(5): 1230–43PubMedCrossRef
81.
Wang J, Wang HX, Ng TB. A peptide with HIV-1 reverse transcriptase inhibitory activity from the medicinal mushroom Russula paludosa. Peptides 2007 Mar; 28(3): 560–5PubMedCrossRef
82.
Oroszlan S, Luftig RB. Retroviral proteinases. Curr Top Microbiol Immunol 1990; 157: 153–85PubMedCrossRef
83.
Pearl LH, Taylor WR. A structural model for the retroviral proteases. Nature 1987; 329(6137): 351–4PubMedCrossRef
84.
Wlodawer A, Miller M, Jaskolski M, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989; 245(4918): 616–21PubMedCrossRef
85.
Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27: 249–84PubMedCrossRef
86.
Carrillo A, Stewart KD, Sham HL, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72(9): 7532–41PubMed
87.
Marciniszyn Jr J, Hartsuck JA, Tang J. Mode of inhibition of acid proteases by pepstatin. J Biol Chem 1976; 251(22): 7088–94PubMed
88.
Marciniszyn Jr J, Hartsuck JA, Tang J. Pepstatin inhibition mechanism. Adv Exp Med Biol 1977; 95: 199–210PubMed
89.
Agarwal NS, Rich DH. Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin. J Med Chem 1986; 29(12): 2519–24PubMedCrossRef
90.
Kay J, Afting EG, Aoyagi T, et al. The effects of lactoyl-pepstatin and the pepsin inhibitor peptide on pig cathepsin D. Biochem J 1982; 203(3): 795–7PubMed
91.
Fitzgerald PM, McKeever BM, VanMiddlesworth JF, et al. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. J Biol Chem 1990; 265(24): 14209–19PubMed
92.
Copeland TD, Wondrak EM, Tozser J, et al. Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor. Biochem Biophys Res Commun 1990; 169(1): 310–4PubMedCrossRef
93.
Young SD, Payne LS, Thompson WJ, et al. HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1′ side chain on structure-activity. J Med Chem 1992; 35(10): 1702–9PubMedCrossRef
94.
Thompson WJ, Fitzgerald PM, Holloway MK, et al. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1′ phenyl substituents: x-ray crystal structure assisted design. J Med Chem 1992; 35(10): 1685–701PubMedCrossRef
95.
Weber IT, Wu J, Adomat J, et al. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate: interactions with frequently occurring glutamic acid residue at P2′ position of substrates. Eur J Biochem 1997; 249(2): 523–30PubMedCrossRef
96.
Miller M, Schneider J, Sathyanarayana BK, et al. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3Å resolution. Science 1989; 246(4934): 1149–52PubMedCrossRef
97.
Grobelny D, Wondrak EM, Galardy RE, et al. Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. Biochem Biophys Res Commun 1990; 169(3): 1111–6PubMedCrossRef
98.
Ghosh AK, Thompson WJ, Holloway MK, et al. Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands. J Med Chem 1993; 36(16): 2300–10PubMedCrossRef
99.
Qasmi D, de Rosny E, Rene L, et al. Synthesis of N-glyoxylyl peptides and their in vitro evaluation as HIV-1 protease inhibitors. Bioorg Med Chem 1997; 5(4): 707–14PubMedCrossRef
100.
Jaskolski M, Tomasselli AG, Sawyer TK, et al. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry 1991; 30(6): 1600–9PubMedCrossRef
101.
Jaskolski M, Miller M, Rao JK, et al. Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2-A resolution. Biochemistry 1990; 29(25): 5889–98PubMedCrossRef
102.
Murthy KH, Winborne EL, Minnich MD, et al. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations. J Biol Chem 1992; 267(32): 22770–8PubMed
103.
Dukes CS, Matthews TJ, Lambert DM, et al. Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates. AIDS Res Hum Retroviruses 1996; 12(9): 777–82PubMedCrossRef
104.
Alteri E, Bold G, Cozens R, et al. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother 1993; 37(10): 2087–92PubMedCrossRef
105.
Sakurai M, Higashida S, Sugano M, et al. Studies of HIV-1 protease inhibitors: II, incorporation of four types of hydroxyethylene dipeptide isosteres at the scissile site of substrate sequences. Chem Pharm Bull (Tokyo) 1993; 41(8): 1378–86CrossRef
106.
Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44(8): 2093–9PubMedCrossRef
107.
Engstrom K, Henry R, Hollis LS, et al. An efficient, stereoselective synthesis of the hydroxyethylene dipeptide isostere core for the HIV protease inhibitor A-792611. J Org Chem 2006; 71(14): 5369–72PubMedCrossRef
108.
Jungheim LN, Shepherd TA, Baxter AJ, et al. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands. J Med Chem 1996; 39(1): 96–108PubMedCrossRef
109.
Kiso Y, Matsumoto H, Mizumoto S, et al. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Biopolymers 1999; 51(1): 59–68PubMedCrossRef
110.
Yoshimura K, Feldman R, Kodama E, et al. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylene cyclopropane nucleoside analogues. Antimicrob Agents Chemother 1999; 43(10): 2479–83PubMed
111.
Mimoto T, Hattori N, Takaku H, et al. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethyl carbonyl isostere. Chem Pharm Bull (Tokyo) 2000; 48(9): 1310–26CrossRef
112.
Baldwin ET, Bhat TN, Gulnik S, et al. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 1995; 3(6): 581–90PubMedCrossRef
113.
Baldwin ET, Bhat TN, Gulnik S, et al. Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine. Adv Exp Med Biol 1995; 362: 445–9PubMedCrossRef
114.
Velazquez-Campoy A, Luque I, Todd MJ, et al. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci 2000; 9(9): 1801–9PubMedCrossRef
115.
Sheha MM, Mahfouz NM, Hassan HY, et al. Synthesis of di- and tripeptide analogues containing alpha-ketoamide as a new core structure for inhibition of HIV-1 protease. Eur J Med Chem 2000; 35(10): 887–94PubMedCrossRef
116.
Mimoto T, Terashima K, Nojima S, et al. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure. Bioorg Med Chem 2004; 12(1): 281–93PubMedCrossRef
117.
Chellappan S, Kiran Kumar Reddy GS, Ali A, et al. Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des 2007; 69(5): 298–313PubMedCrossRef
118.
Chellappan S, Kairys V, Fernandes MX, et al. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins 2007; 68(2): 561–7PubMedCrossRef
119.
Kotier M, Simm M, Zhao YS, et al. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol 1997; 71(8): 5774–81
120.
Potash MJ, Bentsman G, Muir T, et al. Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc Natl Acad Sci U S A 1998; 95(23): 13865–8PubMedCrossRef
121.
Baraz L, Friedler A, Blumenzweig I, et al. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. FEBS Lett 1998; 441(3): 419–26PubMedCrossRef
122.
Friedler A, Blumenzweig I, Baraz L, et al. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors. J Mol Biol 1999; 287(1): 93–101PubMedCrossRef
123.
Blumenzweig I, Baraz L, Friedler A, et al. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases. Biochem Biophys Res Commun 2002; 292(4): 832–40PubMedCrossRef
124.
Sluis-Cremer N, Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem 2002; 269(21): 5103–11PubMedCrossRef
125.
Camarasa MJ, Velazquez S, San-Felix A, et al. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes. Antiviral Res 2006; 71(2-3): 260–7PubMedCrossRef
126.
Zhang ZY, Poorman RA, Maggiora LL, et al. Dissociative inhibition of dimeric enzymes: kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J Biol Chem 1991; 266(24): 15591–4PubMed
127.
Babe LM, Rose J, Craik CS. Synthetic “interface” peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci 1992; (10): 1244–53CrossRef
128.
Schramm HJ, Nakashima H, Schramm W, et al. HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease. Biochem Biophys Res Commun 1991; 179(2): 847–51PubMedCrossRef
129.
Schramm HJ, Billich A, Jaeger E, et al. The inhibition of HIV-1 protease by interface peptides. Biochem Biophys Res Commun 1993; 194(2): 595–600PubMedCrossRef
130.
Schramm HJ, Boetzel J, Buttner J, et al. The inhibition of human immunodeficiency virus proteases by ‘interface peptides’. Antiviral Res 1996; 30(2–3): 155–70PubMedCrossRef
131.
Franciskovich J, Houseman K, Mueller R, et al. A systematic evaluation of the inhibition of HIV-1 protease by its C- and N-terminal peptides. Bioorg Med Chem Lett 1993; 3(4): 765–8CrossRef
132.
Schramm HJ, Breipohl G, Hansen J, et al. Inhibition of HIV-1 protease by short peptides derived from the terminal segments of the protease. Biochem Biophys Res Commun 1992; 184(2): 980–5PubMedCrossRef
133.
Schramm HJ, de Rosny E, Reboud-Ravaux M, et al. Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol Chem 1999; 380(5): 593–6PubMedCrossRef
134.
Dumond J, Boggetto N, Schramm HJ, et al. Thyroxine-derivatives of lipopeptides: bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease. Biochem Pharmacol 2003; 65(7): 1097–102PubMedCrossRef
135.
Misumi S, Kudo A, Azuma R, et al. The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease. Biochem Biophys Res Commun 1997; 241(2): 275–80PubMedCrossRef
136.
Misumi S, Morikawa Y, Tomonaga M, et al. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. J Biochem (Tokyo) 2004; 135(3): 447–53CrossRef
137.
Bouras A, Boggetto N, Benatalah Z, et al. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J Med Chem 1999; 42(6): 957–62PubMedCrossRef
138.
Merabet N, Dumond J, Collinet B, et al. New constrained “molecular tongs” designed to dissociate HIV-1 protease dimer. J Med Chem 2004; 47(25): 6392–400PubMedCrossRef
139.
Bannwarth L, Kessler A, Pethe S, et al. Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization. J Med Chem 2006; 49(15): 4657–64PubMedCrossRef
140.
Broglia RA, Tiana G, Sutto L, et al. Design of HIV-1-PR inhibitors that do not create resistance: blocking the folding of single monomers. Protein Sci 2005; 14(10): 2668–81PubMedCrossRef
141.
Dyda F, Hickman AB, Jenkins TM, et al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266(5193): 1981–6PubMedCrossRef
142.
Engelman A, Bushman FD, Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J 1993; 12(8): 3269–75PubMed
143.
Engelman A, Liu Y, Chen H, et al. Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. J Virol 1997; 71(5): 3507–14PubMed
144.
Engelman A, Englund G, Orenstein JM, et al. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 1995; 69(5): 2729–36PubMed
145.
Hickman AB, Palmer I, Engelman A, et al. Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase. J Biol Chem 1994; 269(46): 29279–87PubMed
146.
Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369(9569): 1261–9PubMedCrossRef
147.
DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43(1): 1–5PubMedCrossRef
148.
Maroun RG, Gayet S, Benleulmi MS, et al. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 2001; 40(46): 13840–8PubMedCrossRef
149.
de Soultrait VR, Caumont A, Parissi V, et al. A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. J Mol Biol 2002; 318(1): 45–58PubMedCrossRef
150.
Desjobert C, de Soultrait VR, Faure A, et al. Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase. Biochemistry 2004; 43(41): 13097–105PubMedCrossRef
151.
Hehl EA, Joshi P, Kalpana GV, et al. Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol 2004; 78(10): 5056–67PubMedCrossRef
152.
Wu X, Liu H, Xiao H, et al. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol 1999; 73(3): 2126–35PubMed
153.
Hutoran M, Britan E, Baraz L, et al. Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease. Virology 2004; 330(1): 261–70PubMedCrossRef
154.
Oz Gleenberg I, Avidan O, Goldgur Y,et al. Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. J Biol Chem 2005; 280(23): 21987–96PubMedCrossRef
155.
Zawahir Z, Neamati N. Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. Bioorg Med Chem Lett 2006; 16(19): 5199–202PubMedCrossRef
156.
Rosenbluh J, Hayouka Z, Loya S, et al. Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides. J Biol Chem 2007; 282(21): 15743–53PubMedCrossRef
157.
von Schwedler UK, Stuchell M, Muller B, et al. The protein network of HIV budding. Cell 2003; 114(6): 701–13CrossRef
158.
Garzon MT, Lidon-Moya MC, Barrera FN, et al. The dimerization domain of the HIV-1 capsid protein binds a capsid protein-derived peptide: a biophysical characterization. Protein Sci 2004; 13(6): 1512–23PubMedCrossRef
159.
Hoglund S, Su J, Reneby SS, et al. Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. Antimicrob Agents Chemother 2002; 46(11): 3597–605PubMedCrossRef
160.
Niedrig M, Gelderblom HR, Pauli G, et al. Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides. J Gen Virol 1994; 75 (Pt 6): 1469–74PubMedCrossRef
161.
Sticht J, Humbert M, Findlow S, et al. A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 2005; 12(8): 671–7PubMedCrossRef
162.
Martin-Serrano J, Zang T, Bieniasz PD. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 2001; 7(12): 1313–9PubMedCrossRef
163.
Strack B, Calistri A, Craig S, et al. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003; 114(6): 689–99PubMedCrossRef
164.
Martin-Serrano J, Perez-Caballero D, Bieniasz PD. Context-dependent effects of L domains and ubiquitination on viral budding. J Virol 2004; 78(11): 5554–63PubMedCrossRef
165.
Goila-Gaur R, Demirov DG, Orenstein JM, et al. Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 over-expression. J Virol 2003; 77(11): 6507–19PubMedCrossRef
166.
Demirov DG, Ono A, Orenstein JM, et al. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A 2002; 99(2): 955–60PubMedCrossRef
167.
Bouamr F, Houck-Loomis BR, De Los Santos M, et al. The C-terminal portion of the Hrs protein interacts with Tsg101 and interferes with human immunodeficiency virus type 1 Gag particle production. J Virol 2007; 81(6): 2909–22PubMedCrossRef
168.
Munshi UM, Kim J, Nagashima K, et al. An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. J Biol Chem 2007; 282(6): 3847–55PubMedCrossRef
169.
Usami Y, Popov S, Gottlinger HG. Potent rescue of human immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends on its CHMP4 binding site. J Virol 2007; 81(12): 6614–22PubMedCrossRef
170.
Lee S, Joshi A, Nagashima K, et al. Structural basis for viral late-domain binding to Alix. Nat Struct Mol Biol 2007; 14(3): 194–9PubMedCrossRef
171.
Fisher RD, Chung HY, Zhai Q, et al. Structural and biochemical studies of ALIX/ AIP1 and its role in retrovirus budding. Cell 2007; 128(5): 841–52PubMedCrossRef
172.
Demidov V, Frank-Kamenetskii MD, Egholm M, et al. Sequence selective double stand DNA cleavage by peptide nucleic acid (PNA) targeting using nuclease S1. Nucleic Acids Res 1993; 21(9): 2103–7PubMedCrossRef
173.
Nielsen PE, Egholm M, Berg RH, et al. Sequence-selective recognition of DNA by stand displacement with a thymine-substituted polyamide. Science 1991; 254(5037): 1497–500PubMedCrossRef
174.
Nielsen PE, Egholm M, Berg RH, et al. Peptide nucleic acids (PNAs): potential antisense and anti-gene agents. Anticancer Drug Des 1993; 8(1): 53–63PubMed
175.
Kaushik N, Pandey VN. PNA targeting the PBS and A-loop sequences of HIV-1 genome destabilizes packaged tRNA3(Lys) in the virions and inhibits HIV-1 replication. Virology 2002; 303(2): 297–308PubMedCrossRef
176.
Mayhood T, Kaushik N, Pandey PK, et al. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry 2000; 39(38): 11532–9PubMedCrossRef
177.
Boutimah-Hamoudi F, Leforestier E, Senamaud-Beaufort C, et al. Cellular antisense activity of peptide nucleic acid (PNAs) targeted to HIV-1 polypurine tact (PPT) containing RNA. Nucleic Acids Res 2007; 35(12): 3907–17PubMedCrossRef
178.
Tripathi S, Chaubey B, Ganguly S, et al. Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucleic Acids Res 2005; 33(13): 4345–56PubMedCrossRef
179.
Chaubey B, Tripathi S, Ganguly S, et al. A PNA-tansportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties. Virology 2005; 331(2): 418–28PubMedCrossRef
180.
Tisne C, Dardel F. Optimisation of a peptide library for screening specific RNA ligands by flow-injection NMR. Comb Chem High Throughput Screen 2002; 5(7): 523–9PubMedCrossRef
181.
Tisne C, Guilliere F, Dardel F. NMR-based identification of peptides that specifically recognize the d-arm of tRNA. Biochimie 2005; 87(9–10): 885–8PubMedCrossRef
182.
Chaloin L, Smagulova F, Hariton-Gazal E, et al. Potent inhibition of HIV-1 replication by backbone cyclic peptides bearing the Rev arginine rich motif. J Biomed Sci 2007; 14(5): 565–84PubMedCrossRef
183.
Baraz L, Hutoran M, Blumenzweig I, et al. Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. J Gen Virol 2002; 83 (Pt 9): 2225–30PubMed
184.
Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369: 787–97PubMedCrossRef
185.
Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov 2003; 2(7): 587–93PubMedCrossRef
186.
Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70(12): 8270–6PubMed
187.
Jacobsen H, Yasargil K, Winslow DL, et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995; 206(1): 527–34PubMedCrossRef
188.
Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2(7): 760–6PubMedCrossRef
189.
Schmit JC, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996; 10(9): 995–9PubMedCrossRef
190.
Khurana S, Kennedy M, King LR, et al. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity. J Virol 2005; 79(11): 6791–800PubMedCrossRef
191.
Chackerian B, Briglio L, Albert PS, et al. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/ human immunodeficiency virus. J Virol 2004; 78: 4037–47PubMedCrossRef
192.
Dorfman T, Moore MJ, Guth AC, et al. A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J Biol Chem 2006; 281(39): 28529–35PubMedCrossRef
193.
Zhang MY, Choudhry V, Sidorov IA, et al. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods 2006; 317: 21–30PubMedCrossRef
194.
Okazaki T, Terabe M, Catanzaro AT, et al. Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse tanscriptase inhibitors studied in HLA-A2 tansgenic mice. J Virol 2006; 80(21): 10645–51PubMedCrossRef
195.
Hamburger AE, Kim S, Welch BD, et al. Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 2005; 280(13): 12567–72PubMedCrossRef
196.
He Y, Vassell R, Zaitseva M, et al. Peptides tap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003; 77(3): 1666–71PubMedCrossRef
197.
Gahery-Segard H, Pialoux G, Figueiredo S, et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J Virol 2003; 77(20): 11220–31PubMedCrossRef
198.
Kran AM, Sorensen B, Nyhus J, et al. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004; 18(14): 1875–83PubMedCrossRef
199.
Pinto LA, Berzofsky JA, Fowke KR, et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 1999; 13(15): 2003–12PubMedCrossRef
200.
Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006; 43(4): 500–11PubMedCrossRef
201.
Nagashima KA, Thompson DA, Rosenfield SI, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183: 1121–5PubMedCrossRef
202.
Allaway GP, Davis-Bruno KL, Beaudry GA, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11: 533–9PubMedCrossRef
203.
Zhang XQ, Sorensen M, Fung M, et al. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother 2006; 50: 2231–3PubMedCrossRef
204.
Moore JP, Sattentau QJ, Klasse PJ, et al. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992; 66: 4784–93PubMed
205.
Trkola A, Ketas TJ, Nagashima KA, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001; 75: 579–88PubMedCrossRef
206.
Yoshimura K, Shibata J, Kimura T, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 2005; 20: 2065–73CrossRef
Metadaten
Titel
Peptide Inhibition of HIV-1
Current Status and Future Potential
verfasst von
Dr Neerja Kaushik-Basu
Amartya Basu
Dylan Harris
Publikationsdatum
01.05.2008
Verlag
Springer International Publishing
Erschienen in
BioDrugs / Ausgabe 3/2008
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI
https://doi.org/10.2165/00063030-200822030-00003

Weitere Artikel der Ausgabe 3/2008

BioDrugs 3/2008 Zur Ausgabe

Current Opinion

Calcitonin — A Drug of the Past or for the Future?

Adis Drug Profile

Mecasermin

Adis Drug Evaluation

Omalizumab

Adis Profile Report

Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix™]

Drug Development

Developing Therapeutic Immunoglobulins